Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6279447 | Neuroscience Letters | 2016 | 6 Pages |
Abstract
Herpes simplex encephalitis(HSE) is the most common and serious viral encephalitis in humans. There is a lack of effective medication to date for HSE. A better understanding of the mediators of tissue damage is essential for finding new targets for therapeutic intervention. In this project, we explored the effect of cyclin-dependent kinases inhibitor olomoucine treatment on experimental HSE mice. The following results were obtained: (1) olomoucine increased survival in HSE mice; (2) olomoucine inhibited microglial activation and reduced HSV-1-induced cytokines release; (3) olomoucine prevented neural cells apoptosis and attenuated brain tissue pathological changes following HSV-1 infection; (4) olomoucine reduced brain edema and improved neurological function in HSE. Overall, olomoucine can induce a blunted inflammatory response, maintain the blood vessel wall intact, improve neurological function and increase survival in HSE mice.
Related Topics
Life Sciences
Neuroscience
Neuroscience (General)
Authors
Yu Zhou, Yan-Ping Zeng, Qin Zhou, Jing-xia Guan, Zu-Neng Lu,